- |||||||||| Benlysta (belimumab) / GSK
Trial completion, Combination therapy: BREVAS: Belimumab in Remission of VASculitis (clinicaltrials.gov) - Feb 11, 2017 P3, N=116, Completed, Active, not recruiting --> Completed | Trial primary completion date: May 2017 --> Jul 2015 Active, not recruiting --> Completed
- |||||||||| Benlysta (belimumab) / GSK
Enrollment change, Combination therapy: BREVAS: Belimumab in Remission of VASculitis (clinicaltrials.gov) - Jan 20, 2016 P3, N=100, Active, not recruiting, Trial primary completion date: Aug 2016 --> Apr 2016 N=400 --> 100
- |||||||||| Benlysta (belimumab) / GSK
Enrollment closed, Trial primary completion date, Combination therapy: BREVAS: Belimumab in Remission of VASculitis (clinicaltrials.gov) - Sep 24, 2015 P3, N=400, Active, not recruiting, Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Jan 2017
- |||||||||| Orencia (abatacept) / BMS
Trial primary completion date: ABAVAS: Abatacept in ANCA Associated Vasculitis (clinicaltrials.gov) - Jun 11, 2015 P2, N=7, Terminated, N=100 --> 0 | Not yet recruiting --> Withdrawn Trial primary completion date: Dec 2010 --> Nov 2008
- |||||||||| Enbrel (etanercept) / Pfizer, Amgen
Trial completion: WGET: Etanercept for Wegener's Granulomatosis (clinicaltrials.gov) - Feb 19, 2014 P2/3, N=181, Completed, No longer recruiting --> Completed No longer recruiting --> Completed
- |||||||||| Benlysta (belimumab) / GSK
Enrollment open, Combination therapy: BREVAS: Belimumab in Remission of VASculitis (clinicaltrials.gov) - Aug 21, 2013 P3, N=400, Recruiting, Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||||||| Benlysta (belimumab) / GSK
Enrollment change, Combination therapy: BREVAS: Belimumab in Remission of VASculitis (clinicaltrials.gov) - Dec 5, 2012 P3, N=400, Recruiting, Recruiting --> Active, not recruiting N=300 --> 400
|